Cargando…

Arsenic nano complex induced degradation of YAP sensitized ESCC cancer cells to radiation and chemotherapy

BACKGROUND: Increased reactive oxygen species (ROS) production by arsenic treatment in solid tumors showed to be effective to sensitize cancer cells to chemotherapies. Arsenic nano compounds are known to increase the ROS production in solid tumors. METHODS: In this study we developed arsenic–ferroso...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Wei, Liu, Meiyue, Li, Xia, Zhang, Peng, Li, Jiong, Zhao, Yue, Sun, Guogui, Mao, Weimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756940/
https://www.ncbi.nlm.nih.gov/pubmed/33353561
http://dx.doi.org/10.1186/s13578-020-00508-x
_version_ 1783626649682575360
author Zhou, Wei
Liu, Meiyue
Li, Xia
Zhang, Peng
Li, Jiong
Zhao, Yue
Sun, Guogui
Mao, Weimin
author_facet Zhou, Wei
Liu, Meiyue
Li, Xia
Zhang, Peng
Li, Jiong
Zhao, Yue
Sun, Guogui
Mao, Weimin
author_sort Zhou, Wei
collection PubMed
description BACKGROUND: Increased reactive oxygen species (ROS) production by arsenic treatment in solid tumors showed to be effective to sensitize cancer cells to chemotherapies. Arsenic nano compounds are known to increase the ROS production in solid tumors. METHODS: In this study we developed arsenic–ferrosoferric oxide conjugated Nano Complex (As(2)S(2)–Fe(3)O(4,) AFCNC) to further promote the ROS induction ability of arsenic reagent in solid tumors. We screen for the molecular pathways that are affect by arsenic treatment in ESCC cancer cells. And explored the underlying molecular mechanism for the arsenic mediated degradations of the key transcription factor we identified in the gene microarray screen. Mouse xenograft model were used to further verify the synthetic effects of AFCNC with chemo and radiation therapies, and the molecular target of arsenic treatment is verified with IHC analysis. RESULTS: With gene expression microarray analysis we found Hippo signaling pathway is specifically affected by arsenic treatment, and induced ubiquitination mediated degradation of YAP in KYSE-450 esophageal squamous cell carcinoma (ESCC) cells. Mechanistically we proved PML physically interacted with YAP, and arsenic induced degradation PML mediated the degradation of YAP in ESCC cells. As a cancer stem cell related transcription factor, YAP 5SA over expressions in cancer cells are correlated with resistance to chemo and radiation therapies. We found AFCNC treatment inhibited the increased invasion and migration ability of YAP 5SA overexpressing KYSE-450 cells. AFCNC treatment also effectively reversed protective effects of YAP 5SA overexpression against cisplatin induced apoptosis in KYSE-450 cells. Lastly, with ESCC mouse xenograft model we found AFCNC combined with cisplatin treatment or radiation therapy significantly reduced the tumor volumes in vivo in the xenograft ESCC tumors. CONCLUSIONS: Together, these findings suggested besides ROS, YAP is a potential target for arsenic based therapy in ESCC, which should play an important role in the synthetic effects of arsenic nano complex with chemo and radiation therapy.
format Online
Article
Text
id pubmed-7756940
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77569402020-12-28 Arsenic nano complex induced degradation of YAP sensitized ESCC cancer cells to radiation and chemotherapy Zhou, Wei Liu, Meiyue Li, Xia Zhang, Peng Li, Jiong Zhao, Yue Sun, Guogui Mao, Weimin Cell Biosci Research BACKGROUND: Increased reactive oxygen species (ROS) production by arsenic treatment in solid tumors showed to be effective to sensitize cancer cells to chemotherapies. Arsenic nano compounds are known to increase the ROS production in solid tumors. METHODS: In this study we developed arsenic–ferrosoferric oxide conjugated Nano Complex (As(2)S(2)–Fe(3)O(4,) AFCNC) to further promote the ROS induction ability of arsenic reagent in solid tumors. We screen for the molecular pathways that are affect by arsenic treatment in ESCC cancer cells. And explored the underlying molecular mechanism for the arsenic mediated degradations of the key transcription factor we identified in the gene microarray screen. Mouse xenograft model were used to further verify the synthetic effects of AFCNC with chemo and radiation therapies, and the molecular target of arsenic treatment is verified with IHC analysis. RESULTS: With gene expression microarray analysis we found Hippo signaling pathway is specifically affected by arsenic treatment, and induced ubiquitination mediated degradation of YAP in KYSE-450 esophageal squamous cell carcinoma (ESCC) cells. Mechanistically we proved PML physically interacted with YAP, and arsenic induced degradation PML mediated the degradation of YAP in ESCC cells. As a cancer stem cell related transcription factor, YAP 5SA over expressions in cancer cells are correlated with resistance to chemo and radiation therapies. We found AFCNC treatment inhibited the increased invasion and migration ability of YAP 5SA overexpressing KYSE-450 cells. AFCNC treatment also effectively reversed protective effects of YAP 5SA overexpression against cisplatin induced apoptosis in KYSE-450 cells. Lastly, with ESCC mouse xenograft model we found AFCNC combined with cisplatin treatment or radiation therapy significantly reduced the tumor volumes in vivo in the xenograft ESCC tumors. CONCLUSIONS: Together, these findings suggested besides ROS, YAP is a potential target for arsenic based therapy in ESCC, which should play an important role in the synthetic effects of arsenic nano complex with chemo and radiation therapy. BioMed Central 2020-12-22 /pmc/articles/PMC7756940/ /pubmed/33353561 http://dx.doi.org/10.1186/s13578-020-00508-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhou, Wei
Liu, Meiyue
Li, Xia
Zhang, Peng
Li, Jiong
Zhao, Yue
Sun, Guogui
Mao, Weimin
Arsenic nano complex induced degradation of YAP sensitized ESCC cancer cells to radiation and chemotherapy
title Arsenic nano complex induced degradation of YAP sensitized ESCC cancer cells to radiation and chemotherapy
title_full Arsenic nano complex induced degradation of YAP sensitized ESCC cancer cells to radiation and chemotherapy
title_fullStr Arsenic nano complex induced degradation of YAP sensitized ESCC cancer cells to radiation and chemotherapy
title_full_unstemmed Arsenic nano complex induced degradation of YAP sensitized ESCC cancer cells to radiation and chemotherapy
title_short Arsenic nano complex induced degradation of YAP sensitized ESCC cancer cells to radiation and chemotherapy
title_sort arsenic nano complex induced degradation of yap sensitized escc cancer cells to radiation and chemotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756940/
https://www.ncbi.nlm.nih.gov/pubmed/33353561
http://dx.doi.org/10.1186/s13578-020-00508-x
work_keys_str_mv AT zhouwei arsenicnanocomplexinduceddegradationofyapsensitizedescccancercellstoradiationandchemotherapy
AT liumeiyue arsenicnanocomplexinduceddegradationofyapsensitizedescccancercellstoradiationandchemotherapy
AT lixia arsenicnanocomplexinduceddegradationofyapsensitizedescccancercellstoradiationandchemotherapy
AT zhangpeng arsenicnanocomplexinduceddegradationofyapsensitizedescccancercellstoradiationandchemotherapy
AT lijiong arsenicnanocomplexinduceddegradationofyapsensitizedescccancercellstoradiationandchemotherapy
AT zhaoyue arsenicnanocomplexinduceddegradationofyapsensitizedescccancercellstoradiationandchemotherapy
AT sunguogui arsenicnanocomplexinduceddegradationofyapsensitizedescccancercellstoradiationandchemotherapy
AT maoweimin arsenicnanocomplexinduceddegradationofyapsensitizedescccancercellstoradiationandchemotherapy